Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)

ClinicalTrials.gov ID: NCT00225862

Public ClinicalTrials.gov record NCT00225862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-week, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Intermittent Dosing of Ropinirole in Patients With Restless Legs Syndrome (RLS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A 12-week clinical research study to evaluate the tolerability, efficacy and safety of ropinirole compared to placebo(an inactive sugar pill) in the treatment of patients with RLS in the United States.

Study identification

NCT ID
NCT00225862
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
140 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 79 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2004
Primary completion
Not listed
Completion
Nov 30, 2005
Last update posted
Sep 14, 2016

2005

United States locations

U.S. sites
37
U.S. states
21
U.S. cities
36
Facility City State ZIP Site status
GSK Investigational Site Alabaster Alabama 35007
GSK Investigational Site Jasper Alabama 35501
GSK Investigational Site Peoria Arizona 85381 - 4828
GSK Investigational Site Phoenix Arizona 85032
GSK Investigational Site Northridge California 91325
GSK Investigational Site Oxnard California 93030
GSK Investigational Site Redondo Beach California 90277
GSK Investigational Site Santa Monica California 90404
GSK Investigational Site Fairfield Connecticut 06824
GSK Investigational Site Largo Florida 33773
GSK Investigational Site Pembroke Pines Florida 33026
GSK Investigational Site St. Petersburg Florida 33701
GSK Investigational Site Tampa Florida 33606
GSK Investigational Site Chicago Illinois 60611
GSK Investigational Site Elk Grove Village Illinois 60007
GSK Investigational Site Flossmoor Illinois 60422
GSK Investigational Site Topeka Kansas 66606
GSK Investigational Site Baton Rouge Louisiana 70808
GSK Investigational Site Frederick Maryland 21702
GSK Investigational Site Newton Massachusetts 02459
GSK Investigational Site Newton Center Massachusetts 02459
GSK Investigational Site Bingham Farms Michigan 48025
GSK Investigational Site Edison New Jersey 08818
GSK Investigational Site Albuquerque New Mexico 87106
GSK Investigational Site Albuquerque New Mexico 87108
GSK Investigational Site Amherst New York 14226
GSK Investigational Site New Hyde Park New York 11040
GSK Investigational Site Raleigh North Carolina 27607
GSK Investigational Site Concinnati Ohio 45219
GSK Investigational Site Oklahoma City Oklahoma 73112
GSK Investigational Site Lafayette Hill Pennsylvania 19444
GSK Investigational Site Columbia South Carolina 29201
GSK Investigational Site Austin Texas 78756
GSK Investigational Site Plano Texas 75093
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Walla Walla Washington 99362
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00225862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 14, 2016 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00225862 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →